ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2008
Tau-based treatment strategies in neurodegenerative diseases.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Drugs · 2011Pooled it
- Neuronal Count, Brain Injury, and Sustained Cognitive Function in 5×FAD Alzheimer's Disease Mice Fed DHA-Enriched Diets.Biomolecules · 2025Article
- Neurophysiological Progression in Alzheimer's Disease: Insights From Dynamic Causal Modelling of Longitudinal Magnetoencephalography.Human brain mapping · 2025Article
- CHIP and aging: a key regulator of proteostasis and cellular senescence.Biogerontology · 2025Review
- Phytoactive drugs used in the treatment of Alzheimer's disease and dementia.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Characterization of Posttranslationally Modified PHF-1 Tau Peptides Using Gaussian Accelerated Molecular Dynamics Simulation.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Arsenic and Tau Phosphorylation: a Mechanistic Review.Biological trace element research · 2023Review
- Glymphatic Dysfunction Induced Oxidative Stress and Neuro-Inflammation in Major Depression Disorders.Antioxidants (Basel, Switzerland) · 2022Review
- Exosomal noncoding RNAs in central nervous system diseases: biological functions and potential clinical applications.Frontiers in molecular neuroscience · 2022Review
- Novel Therapies for Parkinsonian Syndromes-Recent Progress and Future Perspectives.Frontiers in molecular neuroscience · 2021Review
- Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- A combinatorial native MS and LC-MS/MS approach reveals high intrinsic phosphorylation of human Tau but minimal levels of other key modifications.The Journal of biological chemistry · 2020Article
- Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease.Current neuropharmacology · 2020Review
- Future Therapeutic Perspectives into the Alzheimer's Disease Targeting the Oxidative Stress Hypothesis.Molecules (Basel, Switzerland) · 2019Review
- A combined miRNA-piRNA signature to detect Alzheimer's disease.Translational psychiatry · 2019Article
- Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions.Journal of Alzheimer's disease : JAD · 2019Review
- Melatonin Prevents the Harmful Effects of Obesity on the Brain, Including at the Behavioral Level.Molecular neurobiology · 2018Article
- Neurofibrillary tangles mediated human neuronal tauopathies: insights from fly models.Journal of genetics · 2018Review
- An Overview on the Clinical Development of Tau-Based Therapeutics.International journal of molecular sciences · 2018Review
- Vesicular Axonal Transport is Modified In Vivo by Tau Deletion or Overexpression in Drosophila.International journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofibrillary tangles are a characteristic hallmark of Alzheimer's and other neurodegenerative diseases, such as Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). These diseases are summarized as tauopathies, because neurofibrillary tangles are composed of intracellular aggregates of the microtubule-associated protein tau. The molecular mechanisms of tau-mediated neurotoxicity are not well understood; however, pathologic hyperphosphorylation and aggregation of tau play a central role in neurodegeneration and neuronal dysfunction. The present review, therefore, focuses on therapeutic approaches that aim to inhibit tau phosphorylation and aggregation or to dissolve preexisting tau aggregates. Further experimental therapy strategies include the enhancement of tau clearance by activation of proteolytic, proteasomal, or autophagosomal degradation pathways or anti-tau directed immunotherapy. Hyperphosphorylated tau does not bind microtubules, leading to microtubule instability and transport impairment. Pharmacological stabilization of microtubule networks might counteract this effect. In several tauopathies there is a shift toward four-repeat tau isoforms, and interference with the splicing machinery to decrease four-repeat splicing might be another therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.